|
|||||
|
|
Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group) |
|
| Authors: | Hyman B. Muss Brian N. Bundy Howard D. Homesley George Wilbanks |
| Affiliation: | (1) Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC, USA;(2) Associate Group Biostatistician, Gynecologic Oncology Group, Cancer Research Scientist III, Roswell Park Memorial Institute, Buffalo, NY;(3) Department of Obstetrics and Gynecology, Section on Gynecologic Oncology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC;(4) Department of Obstetrics and Gynecology, Rush Medical College, Rush Presbyterian St. Luke's Medical Center, Chicago, IL |
| Abstract: | Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m2 every three weeks. All patients had good performance status and measurable disease and only 11 had received prior chemotherapy. One complete and one partial response were noted among 15 patients with no prior chemotherapy while no responses were seen in 11 previously treated patients. The major toxicity was myelosuppression; other toxicity was mild. The median progression-free interval was 2.1 months and median survival 4.3 months. Mitoxantrone displays minimal activity in patients with advanced non-squamous carcinoma of the cervix. |
| Keywords: | phase II tria mitoxantrone carcinoma of cervix |
| 本文献已被 SpringerLink 等数据库收录！ | |